share_log

Novavax | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(12.26%)

諾瓦瓦克斯醫藥 | SC 13G/A:超過5%持股股東披露文件(修正)-The Vanguard Group(12.26%)

SEC announcement ·  02/13 22:43
Moomoo AI 已提取核心訊息
The Vanguard Group has filed an amended Schedule 13G/A with the Securities and Exchange Commission (SEC) on February 13, 2024, indicating a change in their holdings of Novavax Inc. common stock. As of December 29, 2023, The Vanguard Group reported an aggregate beneficial ownership of 14,560,054 shares of Novavax, which represents 12.26% of the company's class of common stock. The filing, which is an update to previous disclosures, shows that The Vanguard Group has sole dispositive power over 14,304,541 shares and shared dispositive power over 255,513 shares, with shared voting power on 154,553 shares. The Vanguard Group, based in Pennsylvania, has stated that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Novavax Inc.
The Vanguard Group has filed an amended Schedule 13G/A with the Securities and Exchange Commission (SEC) on February 13, 2024, indicating a change in their holdings of Novavax Inc. common stock. As of December 29, 2023, The Vanguard Group reported an aggregate beneficial ownership of 14,560,054 shares of Novavax, which represents 12.26% of the company's class of common stock. The filing, which is an update to previous disclosures, shows that The Vanguard Group has sole dispositive power over 14,304,541 shares and shared dispositive power over 255,513 shares, with shared voting power on 154,553 shares. The Vanguard Group, based in Pennsylvania, has stated that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Novavax Inc.
Vanguard集團已於2024年2月13日向美國證券交易委員會(SEC)提交了經修訂的附表13G/A,表明其持有的Novavax Inc.普通股發生了變化。截至2023年12月29日,Vanguard集團報告稱,Novavax的總受益所有權爲14,560,054股,佔該公司普通股類別的12.26%。該文件是對先前披露的更新,顯示Vanguard集團擁有對14,304,541股股票的唯一處置權,對255,513股股票擁有共同處置權,對154,553股股票擁有共享投票權。總部位於賓夕法尼亞州的Vanguard集團表示,這些證券是在正常業務過程中收購的,不是爲了改變或影響Novavax Inc.的控制權。
Vanguard集團已於2024年2月13日向美國證券交易委員會(SEC)提交了經修訂的附表13G/A,表明其持有的Novavax Inc.普通股發生了變化。截至2023年12月29日,Vanguard集團報告稱,Novavax的總受益所有權爲14,560,054股,佔該公司普通股類別的12.26%。該文件是對先前披露的更新,顯示Vanguard集團擁有對14,304,541股股票的唯一處置權,對255,513股股票擁有共同處置權,對154,553股股票擁有共享投票權。總部位於賓夕法尼亞州的Vanguard集團表示,這些證券是在正常業務過程中收購的,不是爲了改變或影響Novavax Inc.的控制權。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息